skip to main content
Idioma:
Mostrar Somente
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)

Bar, J. ; Kian, W. ; Wolner, M. ; Derijcke, S. ; Girard, N. ; Rottenberg, Y. ; Dudnik, E. ; Metro, G. ; Hochmair, M.J. ; Aboubakar, F. ; Cuppens, K. ; Decoster, L. ; Reck, M. ; Limon, D. ; Blanco, A. Calles ; Astaras, C. ; Häfliger, S. ; Peled, N. ; Addeo, A.

Annals of oncology, 2021-09, Vol.32, p.S961-S962 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F. ; Scherpereel, A. ; Gorbunova, V. ; Gervais, R. ; Vikström, A. ; Chouaid, C. ; Chella, A. ; Kim, J.H. ; Ahn, M.J. ; Reck, M. ; Pazzola, A. ; Kim, H.T. ; Aerts, J.G ; Morando, C. ; Loundou, A. ; Groen, H.J.M. ; Rittmeyer, A.

Annals of oncology, 2014-05, Vol.25 (5), p.1044-1052 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (M022089) randomized phase III trial
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (M022089) randomized phase III trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (M022089) randomized phase III trial

BARLESI, F ; SCHERPEREEL, A ; PAZZOLA, A ; KIM, H. T ; AERTS, J. G ; MORANDO, C ; LOUNDOU, A ; GROEN, H. J. M ; RITTMEYER, A ; GORBUNOVA, V ; GERVAIS, R ; VIKSTRÖM, A ; CHOUAID, C ; CHELLA, A ; KIM, J. H ; AHN, M. J ; RECK, M

Annals of oncology, 2014, Vol.25 (5), p.1044-1052 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
4
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Bonomi, P.D. ; Gandara, D. ; Hirsch, F.R. ; Kerr, K.M. ; Obasaju, C. ; Paz-Ares, L. ; Bellomo, C. ; Bradley, J.D. ; Bunn Jr, P.A. ; Culligan, M. ; Jett, J.R. ; Kim, E.S. ; Langer, C.J. ; Natale, R.B. ; Novello, S. ; Pérol, M. ; Ramalingam, S.S. ; Reck, M. ; Reynolds, C.H. ; Smit, E.F. ; Socinski, M.A. ; Spigel, D.R. ; Vansteenkiste, J.F. ; Wakelee, H. ; Thatcher, N.

Annals of oncology, 2018-08, Vol.29 (8), p.1701-1709 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Bonomi, P.D ; Gandara, D ; Hirsch, F.R ; Kerr, K.M ; Obasaju, C ; Paz-Ares, L ; Bellomo, C ; Bradley, J.D ; Bunn, P.A ; Culligan, M ; Jett, J.R ; Kim, E.S ; Langer, C.J ; Natale, R.B ; Novello, S ; Perol, M ; Ramalingam, S.S ; Reck, M ; Reynolds, C.H ; Smit, E.F ; Socinski, M.A ; Spigel, D.R ; Vansteenkiste, J.F ; Wakelee, H ; Thatcher, N

ANNALS OF ONCOLOGY, 2018-08, Vol.29 (8), p.1701-1709 [Periódico revisado por pares]

OXFORD UNIV PRESS

Texto completo disponível

Citações Citado por
6
Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON
Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON
Material Type:
Artigo 		Adicionar ao Meu Espaço

Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON

Brückl, W. ; Laack, E. ; Kortsik, C. ; Schaefer, H. ; Reck, M. ; Maerten, A. ; Hoffmann, C.

Annals of oncology, 2019-04, Vol.30, p.ii49-ii49 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
125PElderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON
125PElderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON
Material Type:
Artigo 		Adicionar ao Meu Espaço

125PElderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON

Brückl, W ; Laack, E ; Kortsik, C ; Schaefer, H ; Reck, M ; Maerten, A ; Hoffmann, C

Annals of oncology, 2019-04, Vol.30 (Supplement_2) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
8
1527PSequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
1527PSequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Material Type:
Artigo 		Adicionar ao Meu Espaço

1527PSequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany

Brückl, W ; Reck, M ; Laack, E ; Hermes, B ; Rawluk, J ; Huber, R M ; Hoffmann, C ; Schueler, A

Annals of oncology, 2019-10, Vol.30 (Supplement_5) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
9
1527P - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
1527P - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Material Type:
Artigo 		Adicionar ao Meu Espaço

1527P - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany

Brückl, W. ; Reck, M. ; Laack, E. ; Hermes, B. ; Rawluk, J. ; Huber, R.M. ; Hoffmann, C. ; Schueler, A.

Annals of oncology, 2019-10, Vol.30, p.v627-v627 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Material Type:
Artigo 		Adicionar ao Meu Espaço

Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany

Brückl, W. ; Reck, M. ; Laack, E. ; Hermes, B. ; Rawluk, J. ; Huber, R.M. ; Hoffmann, C. ; Schueler, A.

Annals of oncology, 2019-10, Vol.30, p.v627 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (143)

Data de Publicação 

De até
Refinar
  1. Antes de2010  (4)
  2. 2010Até2012  (18)
  3. 2013Até2015  (21)
  4. 2016Até2019  (64)
  5. Após 2019  (37)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (142)
  2. Japonês  (9)
  3. Russo  (4)
  4. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.